Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Faricimab - Roche

Next Previous
Drug Profile

Faricimab - Roche

Alternative Names: Faricimab-svoa; RG 7716; RO 6867461; Vabysmo

Latest Information Update: 03 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Genentech; Roche
  • Class Bispecific antibodies; Eye disorder therapies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Preregistration Angioid streaks
  • Phase III Choroidal neovascularisation; Diabetic retinopathy
  • Clinical Phase Unknown Polypoidal choroidal vasculopathy

Most Recent Events

  • 26 May 2026 Chugai Pharmaceutical plans to submit regulatory application in Diabetic retinopathy in Japan in 2028 (Chugai Pharmaceutical pipeline, May 2026)
  • 22 May 2026 Roche completes a phase III POYANG trial in Choroidal Neovascularization (Treatment naive) in Australia, China, France, Germany, Hong Kong, Italy, Poland, Singapore, South Korea, Spain and Taiwan (Intravitreous) (NCT06176352)
  • 11 Sep 2025 Faricimab is still in phase IIIb/IV trials for Polypoidal choroidal vasculopathy in Thailand, Taiwan, Singapore, Malaysia, South Korea, Japan, India, Hong Kong, China (Intravitreous, Injection) (ISRCTN69073386)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top